TrialInvestigational new drugs2018

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.

Laura Graham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.